Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.48 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | GUSB | P08236 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17393713 | 0.94 | LMNA (0.55) | NPBWR1LMNATHRBS1PR1DGAT1 | |
| SCHEMBL17415753 | 0.93 | LMNA (0.52) | NPBWR1LMNATHRBS1PR1PSMD11 | |
| SCHEMBL17393442 | 0.91 | DGAT1 (0.59) | NPBWR1LMNATHRBS1PR1DGAT1 | |
| SCHEMBL17393275 | 0.91 | NPBWR1 (0.49) | NPBWR1LMNATHRBS1PR1DGAT1 | |
| SCHEMBL17393250 | 0.90 | S1PR1 (0.49) | NPBWR1LMNATHRBS1PR1DGAT1 | |
| SCHEMBL17393283 | 0.88 | PSMD11 (0.53) | PSMD11GUSBKDM4ENPC1RAB9A | |
| SCHEMBL17393727 | 0.87 | NR1H4 (0.61) | NPBWR1LMNATHRBS1PR1DGAT1 | |
| SCHEMBL17393388 | 0.86 | LMNA (0.52) | NPBWR1LMNATHRBS1PR1DGAT1 | |
| SCHEMBL17393278 | 0.85 | LMNA (0.57) | NPBWR1LMNATHRBS1PR1DGAT1 | |
| SCHEMBL17393622 | 0.85 | S1PR1 (0.52) | NPBWR1LMNATHRBS1PR1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522907-B2 | Anticancer agent and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-12-20 | — | — | US | claimed |
| EP-2966073-B1 | DERIVATIVES OF 1-(BENZIMIDAZOL-2-YL)-4-(5-PHENYL-1,2,4-OXADIAZOL-3-YL)-BENZENE USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2016-12-14 | — | — | EP | claimed |
| EP-2966073-A1 | DERIVATIVES OF 1-(BENZIMIDAZOL-2-YL)-4-(5-PHENYL-1,2,4-OXADIAZOL-3-YL)-BENZENE USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2016-01-13 | — | — | EP | claimed |
| US-20160002214-A1 | ANTICANCER AGENT AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-01-07 | — | — | US | claimed |
| US-9522907-B2 | Anticancer agent and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-12-20 | — | — | US | disclosed |
| EP-2966073-B1 | DERIVATIVES OF 1-(BENZIMIDAZOL-2-YL)-4-(5-PHENYL-1,2,4-OXADIAZOL-3-YL)-BENZENE USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2016-12-14 | — | — | EP | disclosed |
| EP-2966073-B1 | DERIVATIVES OF 1-(BENZIMIDAZOL-2-YL)-4-(5-PHENYL-1,2,4-OXADIAZOL-3-YL)-BENZENE USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2016-12-14 | — | — | EP | disclosed |
| EP-2966073-A1 | DERIVATIVES OF 1-(BENZIMIDAZOL-2-YL)-4-(5-PHENYL-1,2,4-OXADIAZOL-3-YL)-BENZENE USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2016-01-13 | — | — | EP | disclosed |
| EP-2966073-A1 | DERIVATIVES OF 1-(BENZIMIDAZOL-2-YL)-4-(5-PHENYL-1,2,4-OXADIAZOL-3-YL)-BENZENE USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | Council of Scientific & Industrial Research (IN) | 2016-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002214-A1 | ANTICANCER AGENT AND PROCESS FOR THE PREPARATION THEREOF | ABCC3, CASP3, ABCC4 | NPBWR1 3746/4885LMNA 1911/4885THRB 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.